Base de dados : MEDLINE
Pesquisa : G06.225.383 [Categoria DeCS]
Referências encontradas : 4248 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 425 ir para página                         

  1 / 4248 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29442037
[Au] Autor:Seko T; Usami E; Kimura M; Nakao T; Matsuoka T; Yoshimura T; Kanamori N; Tachi T; Teramachi H
[Ti] Título:A comparative analysis of micafungin and caspofungin for empirical antifungal therapy in antibiotic-unresponsive febrile patients with hematologic malignancies.
[So] Source:Pharmazie;71(8):484-488, 2016 Aug 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:This study was retrospectively carried out to compare the efficacy of echinocandins such as micafungin (MCFG) and caspofungin (CPFG) in the treatment of antibiotic-unresponsive febrile patients with hematologic malignancies. A total of 163 patients received either MCFG or CPFG. We evaluated the efficacy of echinocandin against fever decline in all patients. Fever decline, defined as a body temperature of less than 37.5 °C sustained for more than 48 h without scheduled antipyretic medication. Efficacy assessments showed that the incidence of fever decline was not significantly different between the MCFG and CPFG groups (P=0.599). The median number of days from the start of echinocandin administration to fever decline was 5 in both the MCFG and CPFG groups. Multivariate analysis showed that the use of anti-MRSA drugs (HR, 0.64; 95%CI, 0.45-0.90; P=0.011) and a change from echinocandins to voriconazole or liposomal-amphotericin B (HR, 0.50; 95%CI, 0.30-0.74; P<0.001) are significant risk factors for sustained fever. A significant difference (P=0.002) in incidence of fever decline was however associated with differences in the timing of anti-MRSA drug administration. The median number of days from the start of echinocandin administration to fever decline was 5 when administration of the anti-MRSA drug occurred "simultaneously or prior to echinocandin start" and 11 in the "next day or later of echinocandin start" group. In other words, starting anti-MRSA drug treatment after echinocandin treatment is a risk factor. In conclusion, MCFG and CPFG have similar efficacy as empirical antifungal agents in the treatment of antibioticunresponsive febrile patients with hematopoietic malignancies.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Equinocandinas/uso terapêutico
Febre/tratamento farmacológico
Febre/etiologia
Neoplasias Hematológicas/complicações
Lipopeptídeos/uso terapêutico
Micoses/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Farmacorresistência Fúngica
Feminino
Seres Humanos
Masculino
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Meia-Idade
Micoses/complicações
Estudos Retrospectivos
Fatores de Risco
Infecções Estafilocócicas/tratamento farmacológico
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Echinocandins); 0 (Lipopeptides); F0XDI6ZL63 (caspofungin); R10H71BSWG (micafungin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6612


  2 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29295978
[Au] Autor:Jung B; Park J; Kim N; Li T; Kim S; Bartley LE; Kim J; Kim I; Kang Y; Yun K; Choi Y; Lee HH; Ji S; Lee KS; Kim BY; Shon JC; Kim WC; Liu KH; Yoon D; Kim S; Seo YS; Lee J
[Ad] Endereço:Department of Applied Biology, Dong-A University, Busan, 49315, Korea.
[Ti] Título:Cooperative interactions between seed-borne bacterial and air-borne fungal pathogens on rice.
[So] Source:Nat Commun;9(1):31, 2018 01 02.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bacterial-fungal interactions are widely found in distinct environments and contribute to ecosystem processes. Previous studies of these interactions have mostly been performed in soil, and only limited studies of aerial plant tissues have been conducted. Here we show that a seed-borne plant pathogenic bacterium, Burkholderia glumae (Bg), and an air-borne plant pathogenic fungus, Fusarium graminearum (Fg), interact to promote bacterial survival, bacterial and fungal dispersal, and disease progression on rice plants, despite the production of antifungal toxoflavin by Bg. We perform assays of toxoflavin sensitivity, RNA-seq analyses, lipid staining and measures of triacylglyceride content to show that triacylglycerides containing linolenic acid mediate resistance to reactive oxygen species that are generated in response to toxoflavin in Fg. As a result, Bg is able to physically attach to Fg to achieve rapid and expansive dispersal to enhance disease severity.
[Mh] Termos MeSH primário: Microbiologia do Ar
Burkholderia/fisiologia
Fusarium/fisiologia
Oryza/microbiologia
Sementes/microbiologia
[Mh] Termos MeSH secundário: Burkholderia/metabolismo
Farmacorresistência Fúngica/efeitos dos fármacos
Fusarium/classificação
Fusarium/genética
Perfilação da Expressão Gênica
Regulação Fúngica da Expressão Gênica
Interações Hospedeiro-Patógeno
Interações Microbianas
Mutação
Filogenia
Doenças das Plantas/microbiologia
Pirimidinonas/metabolismo
Pirimidinonas/farmacologia
Triazinas/metabolismo
Triazinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Pyrimidinones); 0 (Triazines); 5N5YI4IP1P (toxoflavin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02430-2


  3 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29274212
[Au] Autor:Modrzewska BD; Kurnatowska, AJ; Khalid K
[Ad] Endereço:Department of Biology and Medical Parasitology, Medical University of Lodz, Hallera Sq. 1, 90-647 Lodz, Poland
[Ti] Título:Drug susceptibility of fungi isolated from ICU patients
[So] Source:Ann Parasitol;63(3):189-198, 2017.
[Is] ISSN:2299-0631
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Candida species can be a reason of infections associated with high morbidity and mortality. The risk of invasive candidosis for patients admitted to intensive care units (ICUs) is increased due to immunosuppressive states, prolonged length of stay, broad-spectrum antibiotics and Candida colonization. The aim of the study was to determine selected properties of fungi isolated from patients treated in the ICUs of hospitals in Lodz. The materials were collected from the oral cavity, the tracheostomy or endotracheal tube and urine from 16 children and 35 adult. In total, 127 samples were examined to differentiate the fungal strains with used morphological and biochemical methods. Candida species were isolated from adult patients (82.9%), but were not isolated from any of the children; C. albicans was the predominant fungus (61.7%), much less frequent were C. glabrata (12.8%), C. tropicalis (6.4%) and C. kefyr, C. dubliniensis (4.3% each).The susceptibility of fungi to antimycotic drugs revealed that almost all of the strains were susceptible to nystatin (97.9%) and to amphotericin B (72.3%), and resistant to fluconazole (72.3%) and ketoconazole (57.5%). No isolation of fungi from children remaining in ICU may be an evidence of high sanitary regime at these wards; fungi from the genus Candida are the etiological factors for ICU infections; 3/5 of them are caused by C. albicans, mostly of the code 2 576 174, characteristic for strains isolated from hospitalized patients; it is necessary to determine the species of the fungus and its susceptibility to drugs, which allows to conduct effective therapy; prophylactic administration of fluconazole leads to an increase in the number of strains resistant to this chemotherapeutic agent; in the antifungal local treatment, nystatin should be a drug of choice as the drug to which most fungi are susceptible.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Candida/efeitos dos fármacos
Candidíase/microbiologia
Farmacorresistência Fúngica
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antifúngicos/uso terapêutico
Criança
Pré-Escolar
Infecção Hospitalar/microbiologia
Feminino
Seres Humanos
Lactente
Recém-Nascido
Unidades de Terapia Intensiva
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171224
[St] Status:MEDLINE
[do] DOI:10.17420/ap6303.105


  4 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202140
[Au] Autor:Nawrot U; Sulik-Tyszka B; Kurzyk E; Mroczynska M; Wlodarczyk K; Wróblewska M; Basak GW; Brillowska-Dabrowska A
[Ad] Endereço:Department of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.
[Ti] Título:Relation of the polymorphism of cyp51A sequence and the susceptibility of Aspergillus fumigatus isolates to triazoles determined by commercial gradient test (Etest) and by reference methods.
[So] Source:Acta Biochim Pol;64(4):631-634, 2017.
[Is] ISSN:1734-154X
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to evaluate the accuracy of commercial gradient test (Etest) in the detection of triazole resistant Aspergillus fumigatus isolates using reference microdilution methods and the analysis of sequences of the cyp 51A gene. The study was performed on twenty clinical isolates which were identified as Aspergillus fumigatus based on the DNA sequences of the ITS1-2 fragment of ribosomal DNA and the ß-tubulin gene, out of them seventeen isolates showed wild-type cyp51A sequence and three were positive for the mutation TR34/L98H. All isolates were tested for the susceptibility to itraconazole (ITZ), voriconazole (VOR) and posaconasole (POS) using microdilution methods, according to EUCAST and CLSI protocols, as well as using Etest. The results of microdilution and Etests were analysed separately according to clinical breakpoints (CBP) defined by EUCAST version 7.0 and epidemiological cut off values (ECV). Etest as well as reference methods excellently recognised the WT isolates, which were susceptible to all tested triazoles, regardless of the method and CBP or ECV criteria used. The Etest recognized three non-WT isolates as resistant or intermediately sensitive to ITZ and POS and one as resistant to VOR. The categorical concordance between Etests and EUCAST and Etests and the CLSI method ranged from 90 to 100%. The interpretation of the results obtained from routine A. fumigatus Etests requires great caution. The use of the confirmative examinations with reference AST methods as well as with molecular tests is recommended.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Aspergillus fumigatus/efeitos dos fármacos
Sistema Enzimático do Citocromo P-450/genética
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão/métodos
Farmacorresistência Fúngica/efeitos dos fármacos
Proteínas Fúngicas/genética
[Mh] Termos MeSH secundário: Aspergillus fumigatus/genética
Farmacorresistência Fúngica/genética
Itraconazol/farmacologia
Testes de Sensibilidade Microbiana/métodos
Polimorfismo Genético
Triazóis/farmacologia
Voriconazol/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Fungal Proteins); 0 (Triazoles); 304NUG5GF4 (Itraconazole); 9035-51-2 (Cytochrome P-450 Enzyme System); EC 1.14.14.- (cytochrome P-450 CYP51A, Aspergillus); JFU09I87TR (Voriconazole)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.18388/abp.2017_1571


  5 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28989052
[Au] Autor:Matowane RG; Wieteska L; Bamal HD; Kgosiemang IKR; Van Wyk M; Manume NA; Abdalla SMH; Mashele SS; Gront D; Syed K
[Ad] Endereço:Unit for Drug Discovery Research, Department of Health Sciences, Faculty of Health and Environmental Sciences, Central University of Technology, Bloemfontein 9300, Free State, South Africa.
[Ti] Título:In silico analysis of cytochrome P450 monooxygenases in chronic granulomatous infectious fungus Sporothrix schenckii: Special focus on CYP51.
[So] Source:Biochim Biophys Acta;1866(1):166-177, 2018 01.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Sporotrichosis is an emerging chronic, granulomatous, subcutaneous, mycotic infection caused by Sporothrix species. Sporotrichosis is treated with the azole drug itraconazole as ketoconazole is ineffective. It is a well-known fact that azole drugs act by inhibiting cytochrome P450 monooxygenases (P450s), heme-thiolate proteins. To date, nothing is known about P450s in Sporothrix schenckii and the molecular basis of its resistance to ketoconazole. Here we present genome-wide identification, annotation, phylogenetic analysis and comprehensive P450 family-level comparative analysis of S. schenckii P450s with pathogenic fungi P450s, along with a rationale for ketoconazole resistance by S. schenckii based on in silico structural analysis of CYP51. Genome data-mining of S. schenckii revealed 40 P450s in its genome that can be grouped into 32 P450 families and 39 P450 subfamilies. Comprehensive comparative analysis of P450s revealed that S. schenckii shares 11 P450 families with plant pathogenic fungi and has three unique P450 families: CYP5077, CYP5386 and CYP5696 (novel family). Among P450s, CYP51, the main target of azole drugs was also found in S. schenckii. 3D modeling of S. schenckii CYP51 revealed the presence of characteristic P450 motifs with exceptionally large reductase interaction site 2. In silico analysis revealed number of mutations that can be associated with ketoconazole resistance, especially at the channel entrance to the active site. One of possible reason for better stabilization of itraconazole, compared to ketoconazole, is that the more extended molecule of itraconazole may form a hydrogen bond with ASN-230. This in turn may explain its effectiveness against S. schenckii vis-a-vis resistant to ketoconazole. This article is part of a Special Issue entitled: Cytochrome P450 biodiversity and biotechnology, edited by Erika Plettner, Gianfranco Gilardi, Luet Wong, Vlada Urlacher, Jared Goldstone.
[Mh] Termos MeSH primário: Antifúngicos/química
Sistema Enzimático do Citocromo P-450/química
Proteínas Fúngicas/química
Genoma Fúngico
Itraconazol/química
Sporothrix/enzimologia
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Antifúngicos/farmacologia
Domínio Catalítico
Cristalografia por Raios X
Sistema Enzimático do Citocromo P-450/genética
Sistema Enzimático do Citocromo P-450/metabolismo
Farmacorresistência Fúngica/genética
Proteínas Fúngicas/antagonistas & inibidores
Proteínas Fúngicas/genética
Proteínas Fúngicas/metabolismo
Expressão Gênica
Seres Humanos
Itraconazol/farmacologia
Cetoconazol/química
Cetoconazol/farmacologia
Simulação de Acoplamento Molecular
Família Multigênica
Filogenia
Plantas/microbiologia
Ligação Proteica
Domínios e Motivos de Interação entre Proteínas
Estrutura Secundária de Proteína
Alinhamento de Sequência
Sporothrix/classificação
Sporothrix/efeitos dos fármacos
Sporothrix/genética
Esporotricose/tratamento farmacológico
Esporotricose/microbiologia
Homologia Estrutural de Proteína
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Fungal Proteins); 304NUG5GF4 (Itraconazole); 9035-51-2 (Cytochrome P-450 Enzyme System); R9400W927I (Ketoconazole)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE


  6 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241891
[Au] Autor:Pagès A; Iriart X; Molinier L; Georges B; Berry A; Massip P; Juillard-Condat B
[Ad] Endereço:CHU de Toulouse, Pharmacie, Toulouse, France. Electronic address: pages.ar@chu-toulouse.fr.
[Ti] Título:Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.
[So] Source:Value Health;20(10):1319-1328, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mortality from intra-abdominal candidiasis in intensive care units (ICUs) is high. It takes many days for peritoneal-fluid fungal culture to become positive, and the recommended empirical antifungal therapy involves excessive costs. Polymerase chain reaction (PCR) should produce results more rapidly than fungal culture. OBJECTIVES: To perform a cost-effectiveness analysis of the combination of several diagnostic and therapeutic strategies to manage Candida peritonitis in non-neutropenic adult patients in ICUs. METHODS: We constructed a decision tree model to evaluate the cost effectiveness. Cost and effectiveness were taken into account in a 1-year time horizon and from the French National Health Insurance perspective. Six strategies were compared: fluconazole or echinocandin as an empirical therapy, plus diagnosis by fungal culture or detection by PCR of all Candida species, or use of PCR to detect most fluconazole-resistant Candida species (i.e., Candida krusei and Candida glabrata). RESULTS: The use of fluconazole empirical treatment and PCR to detect all Candida species is more cost effective than using fluconazole empirical treatment without PCR (incremental cost-effectiveness ratio of €40,055/quality-adjusted life-year). Empirical treatment with echinocandin plus PCR to detect C. krusei and C. glabrata is the most effective strategy, but has an incremental cost-effectiveness ratio of €93,776/quality-adjusted life-year. If the cost of echinocandin decreases, then strategies involving PCR plus empirical echinocandin become more cost-effective. CONCLUSIONS: Detection by PCR of all Candida species and of most fluconazole-resistant Candida species could improve the cost-effectiveness of fluconazole and echinocandin given to non-neutropenic patients with suspected peritoneal candidiasis in ICUs.
[Mh] Termos MeSH primário: Antifúngicos/administração & dosagem
Candida/isolamento & purificação
Candidíase/diagnóstico
Peritonite/diagnóstico
Reação em Cadeia da Polimerase/métodos
[Mh] Termos MeSH secundário: Adulto
Antifúngicos/economia
Candidíase/tratamento farmacológico
Candidíase/microbiologia
Análise Custo-Benefício
Árvores de Decisões
Farmacorresistência Fúngica
Equinocandinas/administração & dosagem
Equinocandinas/economia
Fluconazol/administração & dosagem
Fluconazol/economia
Seres Humanos
Unidades de Terapia Intensiva
Peritonite/tratamento farmacológico
Peritonite/microbiologia
Reação em Cadeia da Polimerase/economia
Anos de Vida Ajustados por Qualidade de Vida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Echinocandins); 8VZV102JFY (Fluconazole)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  7 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28744860
[Au] Autor:Patil A; Majumdar S
[Ad] Endereço:Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS, USA.
[Ti] Título:Echinocandins in antifungal pharmacotherapy.
[So] Source:J Pharm Pharmacol;69(12):1635-1660, 2017 Dec.
[Is] ISSN:2042-7158
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Echinocandins are the newest addition of the last decade to the antifungal armamentarium, which, owing to their unique mechanism of action, selectively target the fungal cells without affecting mammalian cells. Since the time of their introduction, they have come to occupy an important niche in the antifungal pharmacotherapy, due to their efficacy, safety, tolerability and favourable pharmacokinetic profiles. This review deals with the varying facets of echinocandins such as their chemistry, in-vitro and in-vivo evaluations, clinical utility and indications, pharmacokinetic and pharmacodynamic profiles, and pharmacoeconomic considerations. KEY FINDINGS: Clinical studies have demonstrated that the echinocandins - caspofungin, micafungin and anidulafungin - are equivalent, if not superior, to the mainstay antifungal therapies involving amphotericin B and fluconazole. Moreover, echinocandin regimen has been shown to be more cost-effective and economical. Hence, the echinocandins have found favour in the management of invasive systemic fungal infections. CONCLUSIONS: The subtle differences in echinocandins with respect to their pharmacology, clinical therapy and the mechanisms of resistance are emerging at a rapid pace from the current pool of research which could potentially aid in extending their utility in the fungal infections of the eye, heart and nervous system.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Equinocandinas/farmacologia
Lipopeptídeos/farmacologia
Micoses/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Farmacorresistência Fúngica
Equinocandinas/efeitos adversos
Equinocandinas/farmacocinética
Seres Humanos
Lipopeptídeos/efeitos adversos
Lipopeptídeos/farmacocinética
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Echinocandins); 0 (Lipopeptides); 9HLM53094I (anidulafungin); F0XDI6ZL63 (caspofungin); R10H71BSWG (micafungin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1111/jphp.12780


  8 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456312
[Au] Autor:Malandrakis AA; Vattis KN; Markoglou AN; Karaoglanidis GS
[Ad] Endereço:Pesticide Science Laboratory, Agricultural University of Athens, 75 Iera Odos, 118 55 Athens, Greece. Electronic address: tasmal@aua.gr.
[Ti] Título:Characterization of boscalid-resistance conferring mutations in the SdhB subunit of respiratory complex II and impact on fitness and mycotoxin production in Penicillium expansum laboratory strains.
[So] Source:Pestic Biochem Physiol;138:97-103, 2017 May.
[Is] ISSN:1095-9939
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Laboratory mutants of Penicillium expansum highly resistant (Rfs: 90 to >500, based on EC ) to Succinate Dehydrogenase Inhibitors (SDHIs) were isolated after UV-mutagenesis and selection on media containing boscalid. A positive correlation was found between sensitivity of isolates to boscalid and other SDHIs such as isopyrazam and carboxin but not to fungicides affecting other cellular pathways or processes, such as the triazole flusilazole, the phenylpyrrole fludioxonil, the anilinopyrimidine cyprodinil and the benzimidazole benomyl. Most of the boscalid-resistant strains were more sensitive to the SDHI fluopyram and the QoI pyraclostrobin. In order to investigate the mechanism responsible for the observed resistance profiles, part of the SdhB subunit isolated the wild type and boscalid-resistant isolates, was genetically characterized. Comparison of the deduced amino-acid sequence between resistant and wild-type isolates revealed two point mutations at a position corresponding to codon 272 of the respective SdhB protein in Botrytis cinerea. The substitution of histidine by arginine was found in boscalid-resistant isolates which were equally sensitive to fluopyram compared with the wild-type whereas the replacement of histidine by tyrosine was found in strains with increased sensitivity to fluopyram. No adverse effects of resistance mutations were observed on fitness determining parameters such as osmotic sensitivity, sporulation and pathogenicity, while mycelial growth rate and spore germination was negatively affected in some of the mutants studied. P. expansum mutant strains displayed significantly perturbed patulin and citrinin levels as compared to the wild-type parent strain both in vitro and in vivo as revealed by thin layer (TLC) and high performance liquid chromatography (HPLC).
[Mh] Termos MeSH primário: Compostos de Bifenilo/farmacologia
Complexo II de Transporte de Elétrons/metabolismo
Proteínas Fúngicas/metabolismo
Micotoxinas/metabolismo
Niacinamida/análogos & derivados
Penicillium/efeitos dos fármacos
[Mh] Termos MeSH secundário: Farmacorresistência Fúngica
Proteínas Fúngicas/genética
Fungicidas Industriais/farmacologia
Regulação Fúngica da Expressão Gênica/efeitos dos fármacos
Mutação
Micotoxinas/genética
Niacinamida/farmacologia
Subunidades Proteicas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biphenyl Compounds); 0 (Fungal Proteins); 0 (Fungicides, Industrial); 0 (Mycotoxins); 0 (Protein Subunits); 25X51I8RD4 (Niacinamide); 32MS8ZRD1V (2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide); EC 1.3.5.1 (Electron Transport Complex II); EC 1.6.5.3 (respiratory complex II)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  9 / 4248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456299
[Au] Autor:Li J; Kang T; Talab KMA; Zhu F; Li J
[Ad] Endereço:College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
[Ti] Título:Molecular and biochemical characterization of dimethachlone resistant isolates of Sclerotinia sclerotiorum.
[So] Source:Pestic Biochem Physiol;138:15-21, 2017 May.
[Is] ISSN:1095-9939
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sclerotinia sclerotiorum is a necrotrophic fungal plant pathogen with a broad host range. The dicarboximide fungicide dimethachlone has been used to control this pathogen for more than a decade and resistance to dimethachlone has recently been reported in China. Compared with sensitive isolates, the three dimethachlone resistant isolates with resistance ratios of 78.3, 85.5, and 94.8 exhibited significantly (P<0.05) higher cell membrane permeability and peroxidase and polyphenol oxidase activities. Dimethachlone at 0.25µg/mL significantly increased cell membrane permeability and enhanced activity of the two enzymes in both resistant and sensitive isolates. There were no significant differences in glycerol or oxalate content between the resistant and sensitive isolates. Dimethachlone treatment increased glycerol content in the resistant isolates and reduced in the sensitive isolates (P<0.01). Sequencing of three genes involved in two-component signal pathway and of three genes in mitogen-activated protein (MAP) kinase cascade demonstrated that the dimethachlone resistant isolates HLJ4 and HLJ6 harbored point mutations of I232T and G1087D, respectively, in the deduce amino acid sequence of the histidine kinase (HK) gene Sshk. HLJ4 had a point mutation of P96L in the deduced amino acid sequence of the MAP kinase-kinase gene SsPbs. The expression levels of the Sshk gene were higher in HLJ4 and HLJ6 than in HLJ3 and the sensitive isolate HLJMG2, and transcription of the Sshk gene was up-regulated by dimethachlone for the three resistant isolates.
[Mh] Termos MeSH primário: Ascomicetos/efeitos dos fármacos
Clorobenzenos/farmacologia
Farmacorresistência Fúngica
Fungicidas Industriais/farmacologia
Succinimidas/farmacologia
[Mh] Termos MeSH secundário: Sequência de Bases
Catecol Oxidase/genética
Catecol Oxidase/metabolismo
Clonagem Molecular
Proteínas Fúngicas/genética
Proteínas Fúngicas/metabolismo
Regulação Enzimológica da Expressão Gênica
Regulação Fúngica da Expressão Gênica
Mutação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chlorobenzenes); 0 (Fungal Proteins); 0 (Fungicides, Industrial); 0 (Succinimides); 0 (dimethachlon); EC 1.10.3.1 (Catechol Oxidase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  10 / 4248 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29016668
[Au] Autor:Won EJ; Choi MJ; Shin JH; Park YJ; Byun SA; Jung JS; Kim SH; Shin MG; Suh SP
[Ad] Endereço:Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
[Ti] Título:Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: Comparison between respiratory and ear isolates.
[So] Source:PLoS One;12(10):e0186086, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We analyzed the antifungal susceptibility profiles, genotypes, and virulence of clinical Aspergillus terreus isolates from six university hospitals in South Korea. Thirty one isolates of A. terreus, comprising 15 respiratory and 16 ear isolates were assessed. Microsatellite genotyping was performed, and genetic similarity was assessed by calculating the Jaccard index. Virulence was evaluated by Galleria mellonella survival assay. All 31 isolates were susceptible to itraconazole, posaconazole, and voriconazole, while 23 (74.2%) and 6 (19.4%) showed amphotericin B (AMB) minimum inhibitory concentrations (MICs) of ≤ 1 mg/L and > 4 mg/L, respectively. Notably, respiratory isolates showed significantly higher geometric mean MICs than ear isolates to AMB (2.41 vs. 0.48 mg/L), itraconazole (0.40 vs. 0.19 mg/L), posaconazole (0.16 vs. 0.08 mg/L), and voriconazole (0.76 vs. 0.31 mg/L) (all, P <0.05). Microsatellite genotyping separated the 31 isolates into 27 types, but the dendrogram demonstrated a closer genotypic relatedness among isolates from the same body site (ear or respiratory tract); in particular, the majority of ear isolates clustered together. Individual isolates varied markedly in their ability to kill infected G. mellonella after 72 h, but virulence did not show significant differences according to source (ear or respiratory tract), genotype, or antifungal susceptibility. The current study shows the marked diversity of clinical isolates of A. terreus in terms of antifungal susceptibilities, genotypes and virulence in the G. mellonella model, and ear isolates from Korean hospitals may have lower AMB or triazole MICs than respiratory isolates.
[Mh] Termos MeSH primário: Aspergilose/genética
Aspergillus/efeitos dos fármacos
Farmacorresistência Fúngica/genética
Orelha/microbiologia
Sistema Respiratório/microbiologia
[Mh] Termos MeSH secundário: Animais
Antifúngicos/farmacologia
Aspergilose/tratamento farmacológico
Aspergilose/microbiologia
Aspergillus/patogenicidade
Orelha/patologia
Genótipo
Hospitais Universitários
Seres Humanos
Itraconazol/farmacologia
Lepidópteros/microbiologia
Repetições de Microssatélites/genética
Sistema Respiratório/patologia
Triazóis/farmacologia
Voriconazol/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Triazoles); 304NUG5GF4 (Itraconazole); 6TK1G07BHZ (posaconazole); JFU09I87TR (Voriconazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186086



página 1 de 425 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde